Atyr PHARMA’s (ATYR) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR) in a research report sent to investors on Friday morning,Benzinga reports. HC Wainwright currently has a $35.00 price objective on the stock.

Several other brokerages also recently commented on ATYR. Cantor Fitzgerald assumed coverage on Atyr PHARMA in a report on Monday, January 6th. They set an “overweight” rating on the stock. Leerink Partnrs upgraded Atyr PHARMA to a “strong-buy” rating in a report on Tuesday, February 18th. Finally, Leerink Partners assumed coverage on Atyr PHARMA in a report on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price objective on the stock. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $18.60.

Atyr PHARMA Stock Performance

Shares of NASDAQ:ATYR opened at $3.97 on Friday. The company has a market cap of $333.25 million, a P/E ratio of -4.22 and a beta of 0.98. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. Atyr PHARMA has a one year low of $1.42 and a one year high of $4.66. The business’s 50-day simple moving average is $3.65 and its 200 day simple moving average is $3.08.

Atyr PHARMA (NASDAQ:ATYR) last announced its earnings results on Thursday, March 13th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. On average, sell-side analysts forecast that Atyr PHARMA will post -0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Atyr PHARMA

Institutional investors have recently made changes to their positions in the company. Group One Trading LLC bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at approximately $26,000. Alterna Wealth Management Inc. bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at approximately $36,000. Victory Capital Management Inc. bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at approximately $37,000. Raymond James Financial Inc. bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at approximately $39,000. Finally, XTX Topco Ltd bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at approximately $40,000. 61.72% of the stock is currently owned by institutional investors.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.